Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 301–400 of 1,002
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 61
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment
Pirš, B., Škof, E., Smrkolj, V., & Smrkolj, Š. (2022) · Cancers · doi:10.3390/cancers14030631 · Cited by 52
Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45
Kang, Y., & Cai, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5362 · Cited by 48
Wheatley, R. C., Kilgour, E., Jacobs, T., Lamarca, Á., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01583-8 · Cited by 49
Lian, W., Wang, F., Chen, Y., Tsai, M., Chao, H., Jahr, H., Wu, R., & Ko, J. (2022) · Biomedicines · doi:10.3390/biomedicines10040860 · Cited by 50
The conundrum of breast cancer and microbiome - A comprehensive review of the current evidence
Papakonstantinou, A., Nuciforo, P. G., Borrell, M., Zamora, E., Pimentel, I., Saura, C., & Oliveira, M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102470 · Cited by 51
Gut microbiota and tumor-associated macrophages: potential in tumor diagnosis and treatment
Zhou, D., & Li, Y. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2276314 · Cited by 53
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu, R., Zou, Y., Wang, W.-Q., Chen, J.-H., Zhang, L., Feng, J., Yin, J.-Y., Mao, X.-Y., Li, Q., Luo, Z.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42997-7 · Cited by 45
Exploring the role of gut microbiota in advancing personalized medicine
Huang, G., Khan, R., Zheng, Y., Lee, P.-C., Li, Q., & Khan, I. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1274925 · Cited by 50
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 55
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
Rebeck, O. N., Wallace, M. J., Prusa, J., Ning, J., Evbuomwan, E. M., Rengarajan, S., Habimana-Griffin, L., Kwak, S., Zahrah, D., Tung, J., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.013 · Cited by 49
Fernandes, R., Jabbarizadeh, B., Rajeh, A., Hong, M. M. Y., Baines, K. J., Ernst, S., Winquist, E., Ali, A. S., Penny, S. L., Figueredo, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04183-8 · Cited by 56
Probiotics and probiotic-based vaccines: A novel approach for improving vaccine efficacy
Kazemifard, N., Dehkohneh, A., & Ghavami, S. B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.940454 · Cited by 54
Larroya, A., Pantoja, J., Codoñer‐Franch, P., & Cénit, M. C. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.705859 · Cited by 51
Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
He, Y., Huang, J., Li, Q., Xia, W., Zhang, C., Liu, Z., Xiao, J., Yi, Z., Deng, H., Xiao, Z., et al. (2022) · Cancers · doi:10.3390/cancers14215317 · Cited by 50
Chen, Q., Wu, C., Xu, J., Ye, C., Chen, X., Tian, H., Zong, N., Zhang, S., Li, L., Gao, Y., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.013 · Cited by 50
Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes
Yan, J., Yang, L., Ren, Q., Zhu, C., Du, H., Wang, Z., Qi, Y., Xian, X., & Chen, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471273 · Cited by 55
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Vukadin, S., Khaznadar, F., Kizivat, T., Včev, A., & Smolić, M. (2021) · Biomedicines · doi:10.3390/biomedicines9070835 · Cited by 49
Bacteria in cancer therapy: A new generation of weapons
Fan, J., Huang, Y., Li, Y., Muluh, T. A., Fu, S., & Wu, J. (2022) · Cancer Medicine · doi:10.1002/cam4.4799 · Cited by 46
Brandi, N., & Renzulli, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108598 · Cited by 45
Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
Shtossel, O., Turjeman, S., Riumin, A., Goldberg, M. R., Elizur, A., Bekor, Y., Mor, H., Koren, O., & Louzoun, Y. (2023) · Microbiome · doi:10.1186/s40168-023-01623-w · Cited by 50
Self-citationHuman microbiome acquisition and transmission
Heidrich, V., Valles‐Colomer, M., & Segata, N. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01166-x · Cited by 56
Zhao, Y., Yu, C., Zhang, J., Yao, Q., Zhu, X. M., & Zhou, X. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5651 · Cited by 61
Gut microbial metabolites in cancer immunomodulation
Liu, H., Xiong, X., Zhu, W., Wang, S., Huang, W.-C., Zhu, G., Xu, H., & Yang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02521-5 · Cited by 62
Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy
Bourgin, M., Kepp, O., & Kroemer, G. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2031500 · Cited by 49
Cortiula, F., Hendriks, L. E. L., van de Worp, W. R. P. H., Schols, A. M. W. J., Vaes, R. D. W., LANGEN, R. C. J., & Ruysscher, D. D. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12900 · Cited by 57
Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer
Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S. S., Liu, M., Liang, S., John, E. M., Gomez, S. L., Telli, M. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37636-0 · Cited by 49
Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
de Medeiros, M. C., The, S., Bellile, E. L., Russo, N., Schmitd, L. B., Danella, E. B., Singh, P. A., Banerjee, R., Bassis, C. M., Murphy, G. R., et al. (2023) · Microbiome · doi:10.1186/s40168-023-01677-w · Cited by 50
Zhu, Y., Jian, X., Chen, S., An, G., Jiang, D., Yang, Q. Z., Zhang, J., Hu, J. K., Qiu, Y., Feng, X., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.019 · Cited by 50
Zhu, X., Huang, X., Hu, M., Sun, R., Li, J., Wang, H., Pan, X., Ma, Y., Ning, L., Tong, T., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.03.002 · Cited by 43
Then, C. K., Paillas, S., Moomin, A., Misheva, M., Moir, R., Hay, S. M., Bremner, D. M., Roberts, K. S., Smith, E. E., Heidari, Z., et al. (2024) · Microbiome · doi:10.1186/s40168-024-01804-1 · Cited by 52
Modulating gut microbiota to treat cancer
Woelk, C. H., & Snyder, A. (2021) · Science · doi:10.1126/science.abg2904 · Cited by 42
The emerging potential ofmicrobiome transplantation on human health interventions
Junca, H., Pieper, D. H., & Medina, E. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.009 · Cited by 49
Dey, P., & Chaudhuri, S. R. (2022) · Biology · doi:10.3390/biology11050757 · Cited by 46
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40
“The efficacy of FMT in treating ICI-resistant cancers was demonstrated in two clinical trials (51, 141).”
BackgroundThe Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 48
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Bhamidipati, D., & Subbiah, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.002 · Cited by 49
Tomita, Y., Sakata, S., Imamura, K., Iyama, S., Jodai, T., Saruwatari, K., Hamada, S., Akaike, K., Anai, M., Fukusima, K., et al. (2023) · Cancers · doi:10.3390/cancers16010047 · Cited by 48
Engineered Microorganisms for Advancing Tumor Therapy
Jia, J., Wang, X., Lin, X., & Zhao, Y. (2024) · Advanced Materials · doi:10.1002/adma.202313389 · Cited by 46
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
Murayama, M., Hosonuma, M., Kuramasu, A., Kobayashi, S., Sasaki, A., Baba, Y., Narikawa, Y., Toyoda, H., Isobe, J., Funayama, E., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59677-1 · Cited by 41
Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine
Meza‐Perez, S., Liu, M., Silva-Sánchez, A., Morrow, C. D., Eipers, P. G., Lefkowitz, E. J., Ptacek, T., Scharer, C. D., Rosenberg, A. F., Hill, D. D., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.06.003 · Cited by 44
Macandog, A. D. G., Catozzi, C., Capone, M., Nabinejad, A., Nanaware, P. P., Liu, S., Vinjamuri, S., Stunnenberg, J. A., Galiè, S., Jodice, M. G., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.10.006 · Cited by 40
Current Understanding of Microbiomes in Cancer Metastasis
Liu, J., Luo, F., Wen, L., Zhao, Z., & Sun, H. (2023) · Cancers · doi:10.3390/cancers15061893 · Cited by 45
Unveiling the intratumoral microbiota within cancer landscapes
Che, S., Yan, Z., Feng, Y., & Hai, Z. (2024) · iScience · doi:10.1016/j.isci.2024.109893 · Cited by 44
Influence of the gut microbiota on immune cell interactions and cancer treatment
Liu, C., Fu, L., Wang, Y., & Yang, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05709-3 · Cited by 50
A decade of advances in human gut microbiome-derived biotherapeutics
Pribyl, A. L., Hugenholtz, P., & Cooper, M. A. (2025) · Nature Microbiology · doi:10.1038/s41564-024-01896-3 · Cited by 52
Yang, D., Wang, X., Zhou, X., Zhao, J., Yang, H., Wang, S., Morse, M. A., Wu, J., Yuan, Y., Li, S., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1976953 · Cited by 40
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 45
The Mycobiome: Cancer Pathogenesis, Diagnosis, and Therapy
Gamal, A., Elshaer, M. Y. S., Alabdely, M. H., Kadry, A., McCormick, T. S., & Ghannoum, M. A. (2022) · Cancers · doi:10.3390/cancers14122875 · Cited by 45
The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy
Gholami, H., Chmiel, J. A., Burton, J. P., & Vareki, S. M. (2023) · Cancers · doi:10.3390/cancers15041300 · Cited by 43
Zhang, S., Jin, M., Ren, J., Sun, X., Zhang, Z., Luo, Y., & Sun, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114559 · Cited by 41
Wu, J., Dong, W., Pan, Y., Wang, J., Wu, M., & Yu, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1296783 · Cited by 52
Exploring the gut microbiota and its potential as a biomarker in gliomas
Aljarrah, D., Chalour, N., Zorgani, A., Nissan, T. A., & Pranjol, M. Z. I. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116420 · Cited by 40
Past, present, and future of microbiome-based therapies
Manrique, P., Montero, I., Fernández-Gosende, M., Martínez, N., Hidalgo-Cantabrana, C., & Ríos-Covián, D. (2024) · Microbiome Research Reports · doi:10.20517/mrr.2023.80 · Cited by 50
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.03.001 · Cited by 45
Gut Microbiota Modulation through Akkermansia spp . Supplementation Increases CAR T-cell Potency
Marcos-Kovandzic, L., Avagliano, M., Khelil, M. B., Srikanthan, J., Abdallah, R., Petrocelli, V., Rengassamy, J., Alfaro, A., Bied, M., Fidelle, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1230 · Cited by 45
Hadi, D. K., Baines, K. J., Jabbarizadeh, B., Miller, W. H., Jamal, R., Ernst, S., Logan, D., Bélanger, K., Esfahani, K., Elkrief, A., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012659 · Cited by 48
Bachem, A., Clarke, M. V., Kong, G., Tarasova, I., Dryburgh, L., Kosack, L., Lee, A. R., Newland, L. G. M., Wagner, T., Bawden, E., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.004 · Cited by 51
Schubert, M., Rohrbach, R., Schmitt, M. W., & Stein‐Thoeringer, C. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670286 · Cited by 40
Li, Y., Meng, Y., Sun, H., Ye, L., Zeng, F., Chen, X., & Deng, G. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000392 · Cited by 41
Gut microbial metabolites in cancer therapy
Song, P., Peng, Z., & Guo, X. (2025) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.06.016 · Cited by 38
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer
Montégut, L., de Cabo, R., Zitvogel, L., & Kroemer, G. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0504 · Cited by 38
Gut microbiota shapes social dominance through modulating HDAC2 in the medial prefrontal cortex
Wang, T., Xu, J., Xu, Y., Xiao, J., Bi, N., Gu, X., & Wang, H.-L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110478 · Cited by 39
Boesch, M., Horvath, L., Baty, F., Pircher, A., Wolf, D. G. F., Spahn, S., Straussman, R., Tilg, H., & Brutsche, M. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005401 · Cited by 48
CAR-T Cell Therapy and the Gut Microbiota
Asokan, S., Cullin, N., Stein‐Thoeringer, C. K., & Elinav, E. (2023) · Cancers · doi:10.3390/cancers15030794 · Cited by 42
Application of emerging technologies for gut microbiome research
Kwa, W. T., Sundarajoo, S., Toh, K. Y., & Lee, J. W. J. (2023) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2021-432 · Cited by 43
Cheng, S., Han, Z., Dai, D., Li, F., Zhang, X., Lu, M. S., Lü, Z., Wang, X., Zhou, J., Li, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101355 · Cited by 58
Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology
Jin, K., Huang, Y. B., Che, H., & Wu, Y. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70080 · Cited by 59
Rahimi, A. R., Baghernejadan, Z., Hazrati, A., Malekpour, K., Samimi, L. N., Najafi, A., Falak, R., & Khorramdelazad, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118014 · Cited by 43
Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy
Bolte, L. A., Björk, J. R., Gaćeša, R., & Weersma, R. K. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.04.025 · Cited by 41
Chen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00818-3 · Cited by 51
The role of gut microbiota in tumorigenesis and treatment
Xu, J., Liu, M.-T., Tao, T., Zhu, X. M., & Fei, F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111444 · Cited by 45
Research Progress of Fecal Microbiota Transplantation in Liver Diseases
Zhao, Y., Chen, G., Xu, J., Chen, D., Yang, B., Chen, Z., & Wei, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041683 · Cited by 38
Diet-microbiome interactions in cancer
Abdeen, S. K., Mastandrea, I., Stinchcombe, N., Puschhof, J., & Elinav, E. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.013 · Cited by 36
Network approach in liquidomics landscape
Santini, D., Botticelli, A., Galvano, A., Iuliani, M., Incorvaia, L., Gristina, V., Taffon, C., Foderaro, S., Paccagnella, E., Simonetti, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02743-9 · Cited by 37
Computational methods and challenges in analyzing intratumoral microbiome data
Wang, Q., Liu, Z., Ma, A., Li, Z., Liu, B., & Ma, Q. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.01.011 · Cited by 37
“Studies have showcased that fecal microbiota transplantation (FMT) promotes the immunotherapy response in refractory melanoma patients by modulating the gut microbiome [58,59].”
BackgroundMalard, F., Gaugler, B., & Mohty, M. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00223-x · Cited by 38
Stool multi-omics for the study of host–microbe interactions in inflammatory bowel disease
Sauceda, C., Bayne, C. F., Sudqi, K., González, A., Dulai, P. S., Knight, R. D., Gonzalez, D. J., & Gonzalez, C. G. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2154092 · Cited by 41
Wang, M., Zhang, L., Chang, W., & Zhang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096551 · Cited by 45
Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial
Rashidi, A., Ebadi, M., Rehman, T. U., Elhusseini, H., Kazadi, D., Halaweish, H., Khan, M. H., Hoeschen, A. L., Cao, Q., Luo, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2369 · Cited by 38
Self-citationExploring the Role of the Gut and Intratumoral Microbiomes in Tumor Progression and Metastasis
Ševčíková, A., Mladosievičová, B., Mego, M., & Čierniková, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417199 · Cited by 40
Influence of Gut Microbiota-Mediated Immune Regulation on Response to Chemotherapy
Deng, Y., Hou, X., Wang, H., Du, H., & Liu, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17050604 · Cited by 40
The emerging role of bacterial extracellular vesicles in human cancers
Liang, A., Korani, L., Yeung, C. L. S., Tey, S. K., & Yam, J. W. P. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12521 · Cited by 45
Microbiota-mediated mechanisms of mucosal immunity across the lifespan
Iliev, I. D., Blander, J. M., Collins, N., Guo, C., Longman, R., Sonnenberg, G. F., Zeng, M. Y., & Artis, D. (2025) · Nature Immunology · doi:10.1038/s41590-025-02281-w · Cited by 65
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103025 · Cited by 46
Gopalakrishnan, V., Dozier, E. A., Glover, M. S., Novick, S. J., Ford, M. W., Morehouse, C. A., Warrener, P., Caceres, C. S., Hess, S. Y., Sellman, B. R., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071399 · Cited by 39
The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Guillot, N., Roméo, B., Manesh, S. S., Milano, G., Brest, P., Zitvogel, L., Hofman, P., & Mograbi, B. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.004 · Cited by 36
Qu, Z., Tian, P., Yang, B. K., Zhao, J., Wang, G., & Chen, W. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120719 · Cited by 41
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 44
Gut Microbiome-Based Therapeutics in Critically Ill Adult Patients—A Narrative Review
He, S., Lin, F., Hu, X., & Pan, P. (2023) · Nutrients · doi:10.3390/nu15224734 · Cited by 36
Resistance to immune checkpoint inhibitors in gastric cancer
Liu, K., Yuan, S., Wang, C., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1285343 · Cited by 38
Human intestinal microbiome: Role in health and disease
Cantón, R., Ramos, P. D. L., Botella, A. G., García‐Lledó, A., Hernández‐Sampelayo, T., Gómez‐Pavón, J., del Castillo, J. M. G., Martín-Delgado, M. C., Martín‐Sánchez, F. J., Martínez‐Sellés, M., et al. (2024) · Revista Española de Quimioterapia · doi:10.37201/req/056.2024 · Cited by 40
Exploring the role of gut microbiome in autoimmune diseases: A comprehensive review
Wang, H., Cai, Y., Wu, W. ‐., Zhang, M., Dai, Y., & Wang, Q. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103654 · Cited by 45
Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00910-y · Cited by 41
Runge, S., & Rosshart, S. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.702378 · Cited by 41
McLean, A. E. B., Kao, S. C.-H., Barnes, D. J., WONG, K. K. H., Scolyer, R. A., Cooper, W. A., & Kohonen‐Corish, M. R. J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.011 · Cited by 38
Patient-derived cancer models: Valuable platforms for anticancer drug testing
Genta, S., Coburn, B. A., Cescon, D. W., & Spreafico, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976065 · Cited by 40
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.